Liposomal amphotericin B treatment for neonatal fungal infections
Abstract
BACKGROUND: Disseminated fungal infections are a major problem in high risk neonates. Conventional antifungal agents are often unsatisfactory and have a high incidence of severe adverse effects. METHODS: We administered liposomal encapsulated amphotericin B (AmBisome), which is an alternative to conventional amphotericin B, to 40 preterm (mean birth weight, 1090 +/- 313.6 g; mean gestational age, 28.35 +/- 2.13 weeks) and 4 full term (mean birth weight, 3080 +/- 118 g; mean gestational age, 39 +/- 0.7 weeks) newborn infants with a severe fungal infection. RESULTS: Candida albicans was the most frequent fungus isolated (70%). The duration of intravenous AmBisome therapy ranged from 7 to 49 days; the cumulative dose ranged from 7 to 138.8 mg/kg (median, 45.2 mg/kg). Administration of AmBisome was effective in 72.7% of patients; 5 of 6 cases of meningitis also recovered; 63.6% of 33 very low birth weight infants survived. No side effects were observed. CONCLUSIONS: To our knowledge this is the largest study of the treatment of neonates with liposomal amphotericin B, and the results confirm its effectiveness and safety. However, randomized clinical trials are required to establish the most effective administration protocol for AmBisome, i.e. the starting dosage, the maximum effective dosage and the cumulative dosage, and to verify whether the preparation should be associated with another antifungal agent.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Liposomal amphotericin B was used successfully in 5 of 6 cases of Candida meningitis in newborn infants.
“Liposomal amphotericin B was used successfully in 5 of 6 cases of Candida meningitis in newborn infants [235].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [235]
Cites
Ford, R. C., & Eisenberg, S. (1990) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02934-6 · Cited by 2,734 · see citing works
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringdén, O. T. H. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247 · see citing works
Risk factors associated with candidemia in the neonatal intensive care unit
Weese‐Mayer, D. E., Fondriest, D. W., Brouillette, R. T., & Shulman, S. T. (1987) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-198702000-00009 · Cited by 197 · see citing works
Baley, J. E., Meyers, C., Kliegman, R. M., Jacobs, M. R., & Blumer, J. L. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82674-5 · Cited by 184 · see citing works
Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams).
Johnson, D. E., Thompson, T. R., Green, T. P., & Ferrieri, P. (1984) · PubMed · Cited by 174 · see citing works
Faix, R. G. (1984) · The Journal of Pediatrics · doi:10.1016/s0022-3476(84)80433-3 · Cited by 162 · see citing works
Systemic Candidiasis in Very Low-Birth-Weight Infants (<1,500 Grams)
Johnson, D. E., Thompson, T. R., Green, T. P., & Ferrieri, P. (1984) · PEDIATRICS · doi:10.1542/peds.73.2.138 · Cited by 146 · see citing works
Systemic fungal infections in neonates
Ng, P. C. (1994) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.71.2.f130 · Cited by 64 · see citing works
Lackner, H., Schwinger, W., Urban, C., MÜLLER, W., Ritschl, E., Reiterer, F., Kuttnig-Haim, M., Urlesberger, B., & Hauer, C. (1992) · PEDIATRICS · doi:10.1542/peds.89.6.1259 · Cited by 55 · see citing works
Evdoridou, J., Kremenopoulos, G., Roilides, E., & Bibashi, E. (1997) · Infection · doi:10.1007/bf02113589 · Cited by 36 · see citing works
Conventional vs. Liposomal Amphotericin B in Immunosuppressed Children
Zoubek, A., Emminger, W., Schmidmeier, W., Peters, C. A., Pracher, E., Grois, N., & Gadner, H. (1992) · Pediatric Hematology and Oncology · doi:10.3109/08880019209018337 · Cited by 34 · see citing works
Amphotericin B serum levels in pediatric bone marrow transplant recipients.
Emminger, W., Lang, H., Emminger-Schmidmeier, W., et al. (1991) · PubMed · Cited by 28 · see citing works
Jarløv, J. O., Born, P., & Bruun, B. (1995) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549509032745 · Cited by 21 · see citing works
Ringdén, O. T. H., Tollemar, J. G., Tydén, G., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)91698-8 · Cited by 19 · see citing works
SILVA, L. P. D., Amaral, J. M. V., & FERREIRA, N. C. (1993) · PEDIATRICS · doi:10.1542/peds.91.6.1217a · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
Amphotericin B-induced nephrotoxicity: a review.
Fanos, V., & Cataldi, L. (2000) · Journal of Chemotherapy · doi:10.1179/joc.2000.12.6.463 · Cited by 259 · see citing works
- Authors
- SCARCELLA, A., PASQUARIELLO, M. B., GIUGLIANO, B., VENDEMMIA, M., & DE LUCIA, A.
- Affiliations
- Federico II University Hospital (IT)
- Venue
- The Pediatric Infectious Disease Journal
- Published
- 1998-02
- Volume
- 17
- Issue
- 2
- Pages
- 146-148
- ISSN
- 0891-3668 (ISSN-L)
- OpenAlex
- W2036887186
- Cited by
- 135
- References
- 15
- Citations by year
- 2026: 1 · 2022: 1 · 2020: 3 · 2019: 5 · 2018: 5 · 2016: 3 · 2015: 3 · 2014: 8 · 2013: 3 · 2012: 7
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Pediatric Infectious Disease Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Neonatal and Maternal Infections
- Keywords
- liposomal amphotericin B, neonatal fungal infection, disseminated fungal infection, preterm infants, Candida albicans, fungal meningitis, antifungal therapy, treatment efficacy and safety, very low birth weight infants
- MeSH terms
- Amphotericin B, Antifungal Agents, Humans, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases, Liposomes, Mycoses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
